Pharsight

Duetact patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700128 TAKEDA PHARMS USA Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
Jan, 2027

(3 years from now)

US8071130 TAKEDA PHARMS USA Solid preparation
Jun, 2028

(4 years from now)

Duetact is owned by Takeda Pharms Usa.

Duetact contains Glimepiride; Pioglitazone Hydrochloride.

Duetact has a total of 2 drug patents out of which 0 drug patents have expired.

Duetact was authorised for market use on 28 July, 2006.

Duetact is available in tablet;oral dosage forms.

The generics of Duetact are possible to be released after 08 June, 2028.

Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 July, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DUETACT before it's drug patent expiration?
More Information on Dosage

DUETACT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic